Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.009|
|52 Week High||AU$0.009|
|52 Week Low||AU$0.025|
|1 Month Change||-10.00%|
|3 Month Change||-30.77%|
|1 Year Change||-35.71%|
|3 Year Change||-81.25%|
|5 Year Change||-88.75%|
|Change since IPO||-96.40%|
Recent News & Updates
How Does Living Cell Technologies' (ASX:LCT) CEO Pay Compare With Company Performance?
This article will reflect on the compensation paid to Ken Taylor who has served as CEO of Living Cell Technologies...
|LCT||AU Biotechs||AU Market|
Return vs Industry: LCT underperformed the Australian Biotechs industry which returned 3.7% over the past year.
Return vs Market: LCT underperformed the Australian Market which returned 24.4% over the past year.
Stable Share Price: LCT is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: LCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson’s disease. The company was founded in 1987 and is based in Melbourne, Australia.
Living Cell Technologies Fundamentals Summary
|LCT fundamental statistics|
Is LCT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LCT income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.002|
|Net Profit Margin||-544.62%|
How did LCT perform over the long term?See historical performance and comparison
Is Living Cell Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LCT is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: LCT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LCT is good value based on its PB Ratio (4.7x) compared to the AU Biotechs industry average (4.9x).
How is Living Cell Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Living Cell Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Living Cell Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LCT is currently unprofitable.
Growing Profit Margin: LCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LCT is unprofitable, but has reduced losses over the past 5 years at a rate of 24.7% per year.
Accelerating Growth: Unable to compare LCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (48%).
Return on Equity
High ROE: LCT has a negative Return on Equity (-106.06%), as it is currently unprofitable.
How is Living Cell Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: LCT's short term assets (A$1.6M) exceed its short term liabilities (A$265.1K).
Long Term Liabilities: LCT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LCT is debt free.
Reducing Debt: LCT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LCT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LCT has sufficient cash runway for 1 years if free cash flow continues to grow at historical rates of 12.5% each year.
What is Living Cell Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LCT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bernie Tuch (70 yo)
Dr. Bernard Tuch, also known as Bernie, BSc, MBBS (Hons), FRACP, Ph D., GAICD, has been an Interim Chief Executive Officer at Living Cell Technologies Limited since July 16, 2021. He has been the Chairman...
Experienced Management: LCT's management team is considered experienced (2.6 years average tenure).
Experienced Board: LCT's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.9%.
Living Cell Technologies Limited's employee growth, exchange listings and data sources
- Name: Living Cell Technologies Limited
- Ticker: LCT
- Exchange: ASX
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$6.425m
- Shares outstanding: 713.85m
- Website: https://www.lctglobal.com
- Living Cell Technologies Limited
- 330 Collins Street
- Level 7
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/26 07:02|
|End of Day Share Price||2021/10/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.